# Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures

> **NCT01142193** · PHASE3 · COMPLETED · sponsor: **Upsher-Smith Laboratories** · enrollment: 249 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** USL255
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01142193
- **Lead sponsor:** Upsher-Smith Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2012-12
- **Final completion:** 2013-01
- **Target enrollment:** 249 (ACTUAL)
- **Last updated:** 2014-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01142193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01142193, "Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01142193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*